XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00417079 |
Recruitment Status
:
Completed
First Posted
: December 29, 2006
Results First Posted
: December 23, 2010
Last Update Posted
: March 10, 2011
|
Sponsor:
Sanofi
Information provided by:
Sanofi
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type: | Interventional |
---|---|
Study Design: | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Conditions: |
Neoplasms Prostatic Neoplasms |
Interventions: |
Drug: cabazitaxel (XRP6258) (RPR116258) Drug: mitoxantrone Drug: prednisone |

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
---|
Multicenter study: 146 actives sites from 26 countries in Europe, USA, South America and Asia Pacific region. Study initiation date: January 2nd, 2007; study completion date/study cut off date: September 25th, 2009. |
Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
---|
165 patients signed informed consent but were not randomized and considered as screen failure. Intention to Treat Population (ITT or randomized patients): 755 patients (377 mitoxantrone, 378 cabazitaxel). Safety population (treated patients): 742 patients (371 mitoxantrone, 371 cabazitaxel) (Patients not treated: 6 mitoxantrone, 7 cabazitaxel). |
Reporting Groups
Description | |
---|---|
Mitoxantrone + Prednisone | mitoxantrone 12 mg/m^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily |
Cabazitaxel + Prednisone | cabazitaxel 25 mg/m^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily |
Participant Flow: Overall Study
Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | |
---|---|---|
STARTED | 377 [1] | 378 [1] |
COMPLETED | 46 [1] | 105 [1] |
NOT COMPLETED | 331 | 273 |
Disease progression | 267 | 180 |
Adverse Event | 32 | 67 |
Non-compliance to protocol | 0 | 1 |
Lost to Follow-up | 2 | 0 |
Withdrawal by Subject | 17 | 8 |
Not treated | 6 | 7 |
Screened failure | 2 | 1 |
Investigator's decision | 1 | 4 |
Non-confirmed Disease progression | 1 | 1 |
Clinical deterioration | 1 | 0 |
Screening error | 2 | 1 |
Withdrawal by subject's family | 0 | 1 |
Patient unable to come to the clinic | 0 | 1 |
abnormal liver function tests | 0 | 1 |
[1] | Randomized patients |
---|

1. Primary: | Overall Survival [ Time Frame: From the date of randomization up to 104 weeks (study cut-off) ] |
2. Secondary: | Time to Progression Free Survival (PFS) [ Time Frame: From the date of randomization up to 104 weeks (study cut-off) ] |
3. Secondary: | Overall Tumor Response [ Time Frame: From the date of randomization up to 104 weeks (study cut-off) ] |
4. Secondary: | Time to Tumor Progression [ Time Frame: From the date of randomization up to 104 weeks (study cut-off) ] |
5. Secondary: | Time to Prostatic Specific Antigen (PSA) Progression [ Time Frame: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off) ] |
6. Secondary: | PSA (Prostate-Specific Antigen) Response [ Time Frame: from baseline up to 104 weeks (study cut-off) ] |
7. Secondary: | Time to Pain Progression [ Time Frame: from baseline up to 104 weeks (study cut-off) ] |
8. Secondary: | Pain Response [ Time Frame: from baseline up to 104 weeks (study cut-off) ] |

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
---|
No text entered. |